{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:48:51Z","timestamp":1759366131117,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T00:00:00Z","timestamp":1538697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gaceta Sanitaria"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.gaceta.2018.07.012","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T11:00:45Z","timestamp":1542020445000},"page":"61-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model"],"prefix":"10.1016","volume":"34","author":[{"given":"Oliver","family":"Ibarrondo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"\u00c1lvarez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Freundlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arantzazu","family":"Arrospide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Galve-Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Guti\u00e9rrez-Toribio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arrate","family":"Plazaola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Mar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gaceta.2018.07.012_bib0175","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0180","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1186\/s12885-015-1700-4","article-title":"Evaluation of health benefits and harms of the breast cancer screening programme in the Basque Country using discrete event simulation","volume":"15","author":"Arrospide","year":"2015","journal-title":"BMC Cancer."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0185","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0190","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1007\/s13277-014-2107-6","article-title":"Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer","volume":"35","author":"Liu","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0195","unstructured":"National Comprehensive Cancer Network. (Accessed 18\/6\/2014.) Available at: http:\/\/www.nccn.org\/"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0200","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ctrv.2013.09.014","article-title":"Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow","volume":"40","author":"Harbeck","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0205","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0210","first-page":"147","article-title":"Individualization of therapy using Mammaprint: from development to the MINDACT Trial","volume":"4","author":"Mook","year":"2007","journal-title":"Cancer Genomics Proteomics."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0215","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0220","first-page":"189","article-title":"Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals","volume":"10","author":"Mart\u00ednez del Prado","year":"2018","journal-title":"Breast Cancer Dove Med Press."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0225","first-page":"313","article-title":"Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer","volume":"11","author":"Hornberger","year":"2005","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3111\/13696998.2012.722572","article-title":"Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting","volume":"16","author":"Blohmer","year":"2013","journal-title":"J Med Econ."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0235","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-015-3555-4","article-title":"Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland","volume":"153","author":"Smyth","year":"2015","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0240","series-title":"Methods for the economic evaluation of health care programmes.","first-page":"400","author":"Drummond","year":"2005"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0245","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0250","series-title":"Decision modelling for health economic evaluation","first-page":"250","author":"Briggs","year":"2006"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00019053-200826020-00004","article-title":"Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide","volume":"26","author":"Stahl","year":"2008","journal-title":"PharmacoEconomics."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0260","series-title":"Discrete event simulation for health technology assessment.","first-page":"374","author":"Caro","year":"2015"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0265","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0270","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/jnci\/djj210","article-title":"Retrospective cost-effectiveness analysis of screening mammography","volume":"98","author":"Stout","year":"2006","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0275","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jval.2017.10.023","article-title":"Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach","volume":"21","author":"Ramos-Go\u00f1i","year":"2018","journal-title":"Value Health."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0280","unstructured":"Spanish National Health Statistics. Spanish National Health Survey 2011-2012. (Accessed 2\/3\/2017.) Available at: http:\/\/www.ine.es\/dyngs\/INEbase\/en\/operacion.htm?c=Estadistica_C&cid=1254736176783&menu=resultados&secc=1254736195295&idp=1254735573175"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0285","article-title":"Cost-effectiveness modelling using patient-level simulation","volume":"15","author":"Davis","year":"2014","journal-title":"NICE DSU Technical Support Document No."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0290","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1214\/ss\/1032280214","article-title":"Bootstrap confidence intervals","volume":"11","author":"DiCiccio","year":"1996","journal-title":"Stat Sci."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0295","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1157\/13084127","article-title":"An\u00e1lisis coste-efectividad de tipo probabil\u00edstico del tratamiento de la apnea del sue\u00f1o","volume":"20","author":"Mar","year":"2006","journal-title":"Gac Sanit."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0300","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres","year":"2018","journal-title":"Health Econ."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0305","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdr278","article-title":"Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer","volume":"23","author":"Albanell","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0310","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12325-015-0190-8","article-title":"Cost-effectiveness of the 21-gene breast cancer assay in Mexico","volume":"32","author":"Bargall\u00f3-Rocha","year":"2015","journal-title":"Adv Ther."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0315","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/cer.15.18","article-title":"Long-term cost-effectiveness of Oncotype DX\u00ae versus current clinical practice from a Dutch cost perspective","volume":"4","author":"Kip","year":"2015","journal-title":"J Comp Eff Res."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0320","doi-asserted-by":"crossref","first-page":"e 0128880","DOI":"10.1371\/journal.pone.0128880","article-title":"Economic impact of gene expression profiling in patients with early-stage breast cancer in France","volume":"10","author":"Katz","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0325","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jval.2017.04.021","article-title":"Value of information analysis of multiparameter tests for chemotherapy in early breast cancer: the OPTIMA Prelim Trial","volume":"20","author":"Hall","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0330","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ctrv.2017.10.012","article-title":"Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe","volume":"62","author":"Blok","year":"2018","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.gaceta.2018.07.012_bib0335","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.2017.76.5941","article-title":"Cost-effectiveness analyses of the 21-gene assay in breast cancer: systematic review and critical appraisal","volume":"36","author":"Wang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gaceta.2018.07.012_bib0340","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","article-title":"\u00bfQu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a?","volume":"16","author":"Sacrist\u00e1n","year":"2002","journal-title":"Gac Sanit."}],"container-title":["Gaceta Sanitaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911118302140?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911118302140?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:19:13Z","timestamp":1759324753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213911118302140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0213911118302140"],"URL":"https:\/\/doi.org\/10.1016\/j.gaceta.2018.07.012","relation":{},"ISSN":["0213-9111"],"issn-type":[{"type":"print","value":"0213-9111"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model","name":"articletitle","label":"Article Title"},{"value":"Gaceta Sanitaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gaceta.2018.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 SESPAS. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}